|
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) Valation DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHZ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) Bundle
Explorez les perspectives financières de Shenzhen Kangtai Biological Products Co., Ltd. (300601SZ) avec notre calculatrice DCF conviviale! Entrez vos hypothèses concernant la croissance, les marges et les coûts pour calculer la valeur intrinsèque de Shenzhen Kangtai Biological Products Co., Ltd. (300601SZ) et affinez votre approche d'investissement.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,943.3 | 2,261.2 | 3,652.1 | 3,157.4 | 3,477.4 | 4,124.8 | 4,892.6 | 5,803.3 | 6,883.6 | 8,165.0 |
| Revenue Growth, % | 0 | 16.36 | 61.51 | -13.55 | 10.14 | 18.61 | 18.61 | 18.61 | 18.61 | 18.61 |
| EBITDA | 756.8 | 881.6 | 1,898.5 | .4 | 1,295.1 | 1,379.1 | 1,635.8 | 1,940.3 | 2,301.4 | 2,729.8 |
| EBITDA, % | 38.94 | 38.99 | 51.98 | 0.01402961 | 37.24 | 33.43 | 33.43 | 33.43 | 33.43 | 33.43 |
| Depreciation | 84.3 | 106.5 | 433.1 | 229.0 | 240.7 | 289.4 | 343.3 | 407.2 | 483.0 | 572.9 |
| Depreciation, % | 4.34 | 4.71 | 11.86 | 7.25 | 6.92 | 7.02 | 7.02 | 7.02 | 7.02 | 7.02 |
| EBIT | 672.5 | 775.1 | 1,465.4 | -228.6 | 1,054.4 | 1,089.6 | 1,292.5 | 1,533.1 | 1,818.5 | 2,157.0 |
| EBIT, % | 34.6 | 34.28 | 40.13 | -7.24 | 30.32 | 26.42 | 26.42 | 26.42 | 26.42 | 26.42 |
| Total Cash | 505.2 | 3,037.8 | 3,549.5 | 1,458.4 | 1,758.9 | 2,639.5 | 3,130.9 | 3,713.7 | 4,405.0 | 5,225.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,050.7 | 1,613.4 | 1,858.0 | 2,293.3 | 2,819.2 | 2,722.3 | 3,229.1 | 3,830.2 | 4,543.2 | 5,388.9 |
| Account Receivables, % | 54.07 | 71.35 | 50.88 | 72.63 | 81.07 | 66 | 66 | 66 | 66 | 66 |
| Inventories | 228.8 | 436.5 | 1,058.2 | 727.8 | 772.9 | 868.9 | 1,030.7 | 1,222.5 | 1,450.1 | 1,720.0 |
| Inventories, % | 11.77 | 19.31 | 28.97 | 23.05 | 22.22 | 21.07 | 21.07 | 21.07 | 21.07 | 21.07 |
| Accounts Payable | 116.6 | 167.4 | 708.2 | 434.1 | 791.2 | 571.6 | 678.0 | 804.3 | 954.0 | 1,131.5 |
| Accounts Payable, % | 6 | 7.4 | 19.39 | 13.75 | 22.75 | 13.86 | 13.86 | 13.86 | 13.86 | 13.86 |
| Capital Expenditure | -386.6 | -1,226.7 | -2,540.4 | -1,310.4 | -718.5 | -1,698.3 | -2,014.4 | -2,389.4 | -2,834.2 | -3,361.8 |
| Capital Expenditure, % | -19.9 | -54.25 | -69.56 | -41.5 | -20.66 | -41.17 | -41.17 | -41.17 | -41.17 | -41.17 |
| Tax Rate, % | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 |
| EBITAT | 582.3 | 681.5 | 1,286.3 | -89.7 | 965.8 | 856.8 | 1,016.2 | 1,205.4 | 1,429.8 | 1,696.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -882.9 | -1,158.3 | -1,146.5 | -1,550.0 | 274.1 | -770.8 | -1,217.0 | -1,443.6 | -1,712.3 | -2,031.0 |
| WACC, % | 8.04 | 8.04 | 8.04 | 7.77 | 8.07 | 7.99 | 7.99 | 7.99 | 7.99 | 7.99 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5,545.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2,072 | |||||||||
| Terminal Value | -34,574 | |||||||||
| Present Terminal Value | -23,539 | |||||||||
| Enterprise Value | -29,084 | |||||||||
| Net Debt | 1,237 | |||||||||
| Equity Value | -30,321 | |||||||||
| Diluted Shares Outstanding, MM | 1,119 | |||||||||
| Equity Value Per Share | -27.11 |
Benefits You Will Receive
- Genuine 300601SZ Financial Data: Access to historical and projected figures for precise valuation.
- Customizable Inputs: Adjust parameters such as WACC, tax rates, revenue growth, and capital expenditures.
- Automated Calculations: Instantly compute intrinsic value and NPV with real-time updates.
- Scenario Analysis Tools: Explore various scenarios to assess Shenzhen Kangtai’s future performance.
- User-Friendly Design: Crafted for professionals, yet approachable for newcomers.
Key Features
- Comprehensive Historical Data: Access Shenzhen Kangtai Biological Products Co., Ltd.’s (300601SZ) past financial statements along with pre-filled projections.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth rates, and EBITDA margins to suit your analysis.
- Real-Time Calculations: Instantly view the recalculated intrinsic value of Shenzhen Kangtai Biological Products Co., Ltd. (300601SZ).
- Intuitive Visualizations: Interactive dashboard charts illustrate valuation results and essential metrics.
- Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the prebuilt Excel template containing Shenzhen Kangtai Biological Products Co., Ltd.'s data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the key performance metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly access the recalibrated results, including Shenzhen Kangtai Biological Products Co., Ltd.'s intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or to create comprehensive reports.
Why Choose Shenzhen Kangtai Biological Products Co., Ltd. (300601SZ)?
- Precision: Utilize verified financial data for utmost accuracy.
- Adaptability: Tailored for users to experiment with and adjust inputs effortlessly.
- Efficiency: Eliminate the need to create a financial model from the ground up.
- High-Quality: Crafted with the standards and usability expected by top CFOs.
- Intuitive: Simple to navigate, even for those with minimal financial modeling skills.
Who Should Consider This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for portfolio assessments.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decision-making within the company.
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Shenzhen Kangtai Biological Products Co., Ltd. (300601SZ).
- Students and Educators: Utilize real-time data for practicing and teaching financial modeling techniques.
- Biotech Enthusiasts: Gain insights into how biotech firms like Shenzhen Kangtai Biological Products Co., Ltd. (300601SZ) are valued in the market.
Contents of the Template
- Pre-Filled Data: Features Shenzhen Kangtai Biological Products Co., Ltd.'s historical financials and projections.
- Discounted Cash Flow Model: An editable DCF valuation model with automatic calculation capabilities.
- Weighted Average Cost of Capital (WACC): A dedicated worksheet for calculating WACC using custom inputs.
- Key Financial Ratios: Assess Shenzhen Kangtai's profitability, efficiency, and financial leverage.
- Customizable Inputs: Easily modify revenue growth rates, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.